IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by In Depth Partners LLC

In Depth Partners LLC decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 34.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,198 shares of the company’s stock after selling 4,287 shares during the period. IDEXX Laboratories accounts for 4.3% of In Depth Partners LLC’s portfolio, making the stock its 12th largest position. In Depth Partners LLC’s holdings in IDEXX Laboratories were worth $4,142,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $25,000. Ridgewood Investments LLC purchased a new position in shares of IDEXX Laboratories in the second quarter valued at $27,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of IDEXX Laboratories in the second quarter valued at $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Down 0.6 %

Shares of IDXX stock traded down $2.46 during trading on Tuesday, hitting $428.31. 67,726 shares of the company were exchanged, compared to its average volume of 504,752. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The firm has a market capitalization of $35.07 billion, a price-to-earnings ratio of 41.54, a P/E/G ratio of 3.68 and a beta of 1.37. The business’s 50-day simple moving average is $451.91 and its 200 day simple moving average is $477.31. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.53 earnings per share. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IDXX. Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday. They issued an “outperform” rating and a $500.00 target price for the company. Piper Sandler reiterated a “neutral” rating and set a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Finally, Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $546.56.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.